Enlivex LTD. (ENLV) — 20-F Filings
All 20-F filings from Enlivex LTD.. Browse 2 Foreign Annual Report reports with AI-powered summaries and risk analysis.
20-F Filings (2)
-
Enlivex Pivots to Crypto Treasury, Reports Non-Cash Gain Amidst Clinical Losses
— Mar 25, 2026 Risk: high
Enlivex Ltd. (ENLV) reported a dual strategy for the fiscal year ended December 31, 2025, combining clinical development of Allocetra™ for inflammatory conditio -
Enlivex Therapeutics Files 2024 Annual Report
— Apr 30, 2025 Risk: medium
Enlivex Therapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, formerly known as Bioblast Pharma Ltd.,
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX